Asia
Highly specialized global team advising clients on the full range of legal matters across Asia

Fangdd $78 Million - IPO
Fangdd $78 Million – IPO
November 6, 2019
Cooley advised Fangdd on its $78 million initial public offering of 6,000,000 American depositary shares, each representing 25 class A ordinary shares. The underwriters have a 30-day option to purchase up to 900,000 additional shares. The transaction represents Cooley’s first completed IPO out of its newly launched Hong Kong office. Partner Will Cai led the Cooley team advising Fangdd. Founded in 2011 by former real estate agents Yi Duan and Xi Zeng, Fangdd now trades its securities on the Nasdaq Global Select Market under the symbol “DUO.”
Related contacts
Related Practices & Industries

Legend Biotech - $487 Million IPO
Legend Biotech - $487 Million IPO
June 9, 2020
Cooley advised Legend Biotech on its $487.3 million initial public offering of 21,188,750 American Depository Shares (ADSs). Legend Biotech, whose securities now trade on the Nasdaq Global Select Market under the symbol “LEGN”, is global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications. Partners Div Gupta, Rob Phillips, Will Cai, Michael Yu and Rich Segal led the Cooley team.
Related contacts
Related Practices & Industries
Why Cooley
-
Regularly advises Asia-based clients on unique business opportunities and legal challenges across the region, with offices in Shanghai, Beijing, Hong Kong, and Singapore — strategically located to handle the most complicated cross-border matters
-
Highly specialized multilingual team with deep knowledge of each legal system, practice and culture
-
Core corporate capabilities include advising on formation of private investment funds, private financings, cross-border capital markets transactions, life sciences corporate partnering and licensing, joint ventures, mergers and acquisitions, and general corporate matters
-
Organized China’s first dollar-denominated private investment fund in 1989 and advises 80+ investment fund managers
-
Assists in litigation, regulatory and compliance matters for Asia-based companies and individuals, spanning commercial litigation, product compliance, antitrust, internal investigations, trademark and domain name disputes
-
Recognized by China Business Law Journal as the 2019 Private Equity and Venture Capital Firm of the Year and 2019 Healthcare and Life Sciences Firm of the Year
-
Recognized by China Law and Practice Awards as 2019 Healthcare and Life Sciences Law Firm of the Year (International) and 2018 Investment Funds Firm of the Year (International)
Group contacts
